Abstract
Introduction/BackgroundLIO-1 (NCT04042116) assesses the combination of lucitanib, an oral anti-angiogenic, multikinase inhibitor administered using safety-based dose titration, and nivolumab, an inhibitor of programmed cell death receptor 1 (PD-1). Here, we...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have